Bio-Gene Technology Ltd
Bio-Gene Technology Limited is an Australia-based agriculture technology development company enabling the next generation of novel bio-insecticides.
The business
Bio-Gene Technology Limited is an Australia-based agriculture technology development company enabling the next generation of novel bio-insecticides. Its products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment. Its products have multiple applications across crop protection, grain storage, public health and consumer uses. Flavocide and Qcide are the Company’s lead beta-triketone insecticide products. Flavocide is a natural beta-triketone molecule produced synthetically by a chemical process. Qcide is a natural oil product containing tasmanone as the active constituent. The oil is extracted from the leaves of a rare cultivar of an Australian eucalypt, the Gympie Messmate (Eucalyptus cloeziana), by utilizing a steam distillation process. The Company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Small Caps Research
No research on Bio-Gene Technology Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise BGT based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Bio-Gene Technology Targets March 2027 APVMA Submission for Flavocide as Toxicology Studies Continue
Bio-Gene targets APVMA submission for Flavocide in March 2027 as toxicology studies progress, but faces ongoing cash burn and fundraising risk.
Bio-Gene Secures OMRI Approval for Qcide Organic Listing under USDA National Organic Program
Bio-Gene Technology (ASX: BGT) has received approval from the Organic Materials Review Institute in the US to list its Qcide natural insecticide as a Botanical Pesticide under the USDA National Organic Program.
Bio-Gene Reports Strong Flavocide Results Against Ticks to Leading US Lyme Disease Conference
Bio-Gene Technology (ASX: BGT) has released new data confirming that its lead compound Flavocide delivers strong activity against ticks responsible for spreading Lyme disease in the United States. Presented by Purdue University researchers at the International Conference on Lyme Borreliosis and Other Tick-Borne Diseases in Chicago, the findings showed that Flavocide achieved more than 90% […]
Bio-Gene awarded $3m in US grants to develop insecticides for military use
Bio-Gene Technology (ASX: BGT) has been awarded $3 million in grants by the US Department of Defense to develop insecticide products to protect its workforce from threats posed by disease-carrying species including mosquitoes and ticks. The grants have been provided under the government’s Deployed Warfighter Protection research program. The program aims to identify and test […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.